RecruitingNCT01401998
ARPKD Database Study
Studying Autosomal recessive polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Philadelphia
- Principal Investigator
- Lisa Guay-Woodford, MD, CRNPChildren's Hospital of Philadelphia
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2030
Study locations (6)
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Emory, Atlanta, Georgia, United States
- Boston Children's, Boston, Massachusetts, United States
- Cincinnati Children's, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01401998 on ClinicalTrials.govOther trials for Autosomal recessive polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07201025Imaging Assessments of ARPKD Kidney Disease ProgressionThe Cleveland Clinic
- RECRUITINGNCT06601829Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University HospitalSohag University
- RECRUITINGPHASE3NCT04782258A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)Otsuka Pharmaceutical Development & Commercialization, Inc.
See all trials for Autosomal recessive polycystic kidney disease →